EP1384777A1 - Adn genomiques participant a la polyarthrite rhumatoide, son procede de diagnostic, son procede d'estimation du risque d'apparition et trousse de diagnostic de detection associee - Google Patents
Adn genomiques participant a la polyarthrite rhumatoide, son procede de diagnostic, son procede d'estimation du risque d'apparition et trousse de diagnostic de detection associee Download PDFInfo
- Publication number
- EP1384777A1 EP1384777A1 EP02713262A EP02713262A EP1384777A1 EP 1384777 A1 EP1384777 A1 EP 1384777A1 EP 02713262 A EP02713262 A EP 02713262A EP 02713262 A EP02713262 A EP 02713262A EP 1384777 A1 EP1384777 A1 EP 1384777A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- rheumatoid arthritis
- same
- genomic dna
- diagnosing
- detecting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010039073 rheumatoid arthritis Diseases 0.000 title claims abstract description 54
- 238000000034 method Methods 0.000 title claims abstract description 30
- 238000009007 Diagnostic Kit Methods 0.000 title claims abstract description 11
- 230000035772 mutation Effects 0.000 claims abstract description 35
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims abstract description 14
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical class CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims abstract description 14
- 238000006467 substitution reaction Methods 0.000 claims abstract description 9
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical class O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229940104302 cytosine Drugs 0.000 claims abstract description 7
- 229940113082 thymine Drugs 0.000 claims abstract description 7
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims abstract description 4
- 229930024421 Adenine Natural products 0.000 claims abstract description 4
- 229960000643 adenine Drugs 0.000 claims abstract description 4
- 108090000623 proteins and genes Proteins 0.000 description 22
- 108020004414 DNA Proteins 0.000 description 20
- 238000003752 polymerase chain reaction Methods 0.000 description 20
- 239000013615 primer Substances 0.000 description 13
- 238000003745 diagnosis Methods 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 239000012634 fragment Substances 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 5
- 108091092878 Microsatellite Proteins 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 238000000546 chi-square test Methods 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 210000003917 human chromosome Anatomy 0.000 description 3
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 3
- 229940123907 Disease modifying antirheumatic drug Drugs 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000002988 disease modifying antirheumatic drug Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 1
- 208000027932 Collagen disease Diseases 0.000 description 1
- 108020001019 DNA Primers Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 210000001766 X chromosome Anatomy 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000037429 base substitution Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000005546 dideoxynucleotide Substances 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000008407 joint function Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 210000002437 synoviocyte Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Definitions
- the present invention relates to genomic DNAs with mutations, a method of diagnosing human rheumatoid arthritis by using the mutations, a method of judging onset risk thereof, and a diagnostic kit for detecting the same.
- RA Rheumatoid arthritis
- RA Rheumatoid arthritis
- Untreated RA causes a destruction and a deformation of joint, later presenting functional disorders of motor apparatus. Sometimes it threatens lives of patients. Consequently, patients with RA have to bear large, lifelong physical and mental burdens.
- RA results in a large variety of symptoms, and the diagnostic criteria of the American College of Rheumatology are widely used for its diagnosis.
- development of an onset state of RA is generally very slow, requiring a period from several weeks to several months.
- rheumatoid factor which is an objective index in the diagnostic criteria of American College of Rheumatology
- a positive rate is 33% within 3 months and around 88% even after 12 months or more [Chiryo, 73(3): 23-27, 1991]. This indicates that RA cannot be diagnosed definitively at present.
- An attempt to diagnose rheumatoid arthritis by detecting a serum rheumatoid arthritis associated antigen IgM in a patient through a reaction with recombinant antigen has been performed (JP-A-10-513257).
- a therapeutic procedure to be selected is generally varied depending on a progression stage of symptoms in the disease state.
- a nonsteroidal antiinflammatory drug NSAID
- a disease-modifying antirheumatic drug DMARD
- the NSAID is administered, and at the same time, an effort is made to identify this disease from other rheumatic diseases including collagen disease, by carefully observing the symptom and procession.
- steroids may be administered, and a pharmacotherapy for pain together with a physiotherapy and an orthotic therapy are performed in order to maintain and ameliorate joint functions.
- a surgical therapy may be performed in a case in which daily life is inconvenienced by a joint disruption.
- RA is still thought to be a disease which develops and progresses after an onset caused by cooperation with a large number of causative factors including a living environment. For that reason, in order to perform a more exact elucidation of the disease and a proper therapy thereof, an essential part of interactions of the multiple factors involved has to be established. Since RA is a disease with an incident rate of 1% or less in the world (N. Engl. J.
- An object of the present invention is to elucidate further mutations in human Dbl gene and their relations to an onset or an onset risk of RA; and provides a method for precisely diagnosing the onset or the onset risk of RA by utilizing such mutations.
- Another object of the present invention is to provide a diagnostic kit useful for detecting a genomic DNA which is a mutated Db1 gene associating with RA.
- the base (c) at the position-1987 is located in the intron 24, and the bases (t) and (a) at the position-3664 and the position-3769 are located in the intron 23.
- the mutated genomic DNA of the present invention is now known to be partially the cause of the RA onset.
- Such a relationship between single base substitution mutation and diseases is known in other cases such as the gene causative of type II diabetes mellitus (Nature Genetics, 26: 163-175, 2000).
- the present inventors have found from these studies that a method of diagnosing RA, a method of judging the onset risk of RA, and a diagnostic kit for detecting these mutations, by using the mutations of the Dbl gene in cells obtained from examinees as a index, are useful, and accomplished the present invention. Further, the present invention is useful for developments of novel preventive or therapeutic methods and drugs for the treatment of rheumatoid arthritis.
- a, c, g and t mean the bases adenine, cytosine, guanine and thymine, respectively.
- SEQ ID NO: 1 corresponds to the sequence from the position-55,823 to the position-59,696 of the sequence registered in GenBank as the human genome of the X chromosome, q25-26.3 region containing the genomic DNA of the Dbl gene (GenBank accession No. AL033403).
- the sequence registered in GenBank has the following properties: The complementary strand thereof is a +strand; it is translated from the position-115,837 to 5' direction; and it transcribes mRNA of the GenBank accession No. X12556.
- the method of diagnosing RA, the method of judging onset risk thereof, and the diagnostic kit for detecting the same in the present invention detects at least one of the mutations in the genomic DNA previously described.
- Identification of a mutant genomic DNA and diagnosis of RA or judgment of onset risk of RA can be made, for example, as described below.
- a genomic DNA of an examinee can be obtained by the conventional method from any human cells, for example, hair, various organs, peripheral lymphocytes and synovial cells. It can also be obtained from cultured and proliferated cells. In addition, the thus obtained genomic DNA can be used after being amplified by using the conventional gene amplification methods such as PCR (Polymerase chain reaction), NASBA (Nucleic acid sequence based amplification), TMA (Transcription-mediated amplification) and SDA (Strand displacement amplification).
- PCR Polymerase chain reaction
- NASBA Nucleic acid sequence based amplification
- TMA Transcription-mediated amplification
- SDA String displacement amplification
- Detection method for genomic variants is not particularly limited. It includes, for example, allele specific oligonucleotide probe method, oligonucleotide ligation assay method, PCR-SSCP method, PCR-CFLP method, PCR-PHFA method, invader method, RCA (Rolling circle amplification) method and primer oligo base extension method.
- a PCR primer which can amplify the region containing the mutated positions in SEQ ID NO: 1, is synthesized; and then direct sequencing of the PCR product amplified from a genomic DNA of the examinee is carried out to determine the mutation.
- diagnosis of RA of the examinee or onset risk thereof can then be judged precisely.
- the primer used in the present invention can be prepared conventionally by using a DNA synthesizer or the like.
- the mutations described above can also be detected by using a microarray equipped with oligonucleotides consisting of a normal sequence and a mutated sequence in the mutation site penumbra.
- the mutation (t ⁇ g) at the position-3664 can also be detected, as shown in the Examples, by amplifying a +strand of the genomic DNA using a synthetic oligonucleotide containing the mutation site thereof (SEQ ID NO: 2 and SEQ ID NO: 3) as a primer in PCR, cleaving the PCR product with the restriction enzyme Hinf-I, and examining whether the PCR product is fragmented into two fragments or not (RFLP analysis).
- the normal sequence penumbral to the position-3664 in the complementary strand of SEQ ID NO: 1 is 5'-gaatc-3', and is cleaved by Hinf-I (recognition sequence: 5'-g ⁇ antc-3').
- the mutated sequence penumbral to the position-3664 in the complementary strand of SE ID NO: 1 is 5'-gcatc-3', and is not cleaved by Hinf-I.
- a diagnostic kit of the present invention is not particularly limited as long as it contains a reagent such as primer and probe, which can detect at least one mutation of the genomic DNA described above, and can be obtained by further combining other additional reagents.
- kits examples include a combination of a primer which is designed to amplify the genomic region containing at least one mutation described above, and further at least one reagent necessary for detecting the mutation including a prove which is designed to detect the genomic region containing at least one mutation described above, a restriction enzyme and a reagent used for base sequence determination methods such as Maxam-Gilbert method and chain termination method.
- a kit comprising a fluorescence labeled dideoxynucleotide is further included.
- Diagnosis of RA or onset risk thereof can be performed precisely by using the diagnostic kit.
- the diagnostic kit of the present invention can be constructed, for example, in the case of a kit for RFLP analysis of the mutation at the position-3664, by a primer set consisting of base sequences of SEQ ID NO: 2 and SEQ ID NO: 3, restriction enzyme Hinf-I, DNA synthase, and the like. Further, proper buffer, washing solution and the like, which do not disturb the detection of mutation, may be added.
- Genomic DNA was extracted from the peripheral blood. After amplifying the region with about 5.3 kbp penumbral to the exon 23 and 24 which correspond to 223 bp deficient region of Dbl gene cDNA by PCR, the base sequence was determined by Dye Terminator method using a sequence primer (Fig. 1) which was designed based on the previously known genomic sequence (Acc. No. AL033403.1). In the statistical analysis, chi-square test ( ⁇ 2 -test) by the percentage method was used for the test of significance. Base sequence of each primer set used for the PCR is shown as follows:
- nt2632+211(a ⁇ c) corresponds to t ⁇ g mutation at the position-3664 in SEQ ID NO: 1
- nt2745+576(g ⁇ a) corresponds to c ⁇ t mutation at the position-1987 in SEQ ID NO: 1.
- Genomic DNA 1 ⁇ l PCR buffer II (Applied Biosystems Inc.) 2.5 25 mM MgCl 2 1.5 2 mM dNTP 2.5 10 pmol/ ⁇ l sense primer 0.5 10 pmol/ ⁇ l antisense primer 0.5 Gold Taq polymerase 0.25 Sterilized water 16.25
- DNA-amplified reaction mixture was reacted at 37°C for 1 hour with a restriction enzyme Hinf-I (New England Biolabs Inc., recognition sequence: 5'-G ⁇ ANTC-3') using the reaction composition described below to digest completely, and analyzed by the conventional manner using 2.0% agarose gel electrophoresis and ethidium bromide staining.
- PCR reaction mixture 10 ⁇ l Hinf-I 2 ⁇ l Reaction buffer (NE Buffer II) 1.5 ⁇ l Sterilized water 1.5 ⁇ l
- Lane 2 is an electrophoretic pattern of the PCR product after the Hinf-I treatment obtained by using the normal Dbl gene as a template wherein the sequence is cleaved to 227 bp and 144 bp by the Hinf-I recognition sequence (5'-gaatc-3') at the position-3664 (nt2632+211) penumbra.
- Lane 1 is an electrophoretic pattern of the PCR product derived from the homologous variant Dbl gene wherein no cleavage occurs due to disappearance of the Hinf-I recognition sequence by t ⁇ g mutation at the position-3664 (a ⁇ c mutation of nt2632+211).
- Lane 3 is an electrophoretic pattern of the PCR product derived from the heterologous variant Dbl gene. Since a fragment having the Hinf-I recognition sequence and a fragment without having the Hinf-I recognition sequence were amplified, 3 fragments consisting of a non-cleaved fragment of 377 bp and further cleaved 2 fragments of 227 bp and 144 bp were simultaneously detected.
- the present invention relates to genomic DNAs with mutations associated with human rheumatoid arthritis, a method of diagnosing human rheumatoid arthritis by using these mutations, a method of judging onset risk thereof, and a diagnostic kit for detecting the same.
- the present invention is useful for detecting onset of rheumatoid arthritis or onset risk thereof precisely, simply and exactly. Further, the present invention is useful for developing novel preventive and therapeutic methods and therapeutic drugs for rheumatoid arthritis.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001102006 | 2001-03-30 | ||
JP2001102006 | 2001-03-30 | ||
PCT/JP2002/003191 WO2002079466A1 (fr) | 2001-03-30 | 2002-03-29 | Adn genomiques participant a la polyarthrite rhumatoide, son procede de diagnostic, son procede d'estimation du risque d'apparition et trousse de diagnostic de detection associee |
Publications (3)
Publication Number | Publication Date |
---|---|
EP1384777A1 true EP1384777A1 (fr) | 2004-01-28 |
EP1384777A4 EP1384777A4 (fr) | 2005-06-01 |
EP1384777B1 EP1384777B1 (fr) | 2009-05-27 |
Family
ID=18955253
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP02713262A Expired - Lifetime EP1384777B1 (fr) | 2001-03-30 | 2002-03-29 | Adn genomiques participant a la polyarthrite rhumatoide, son procede de diagnostic, son procede d'estimation du risque d'apparition et trousse de diagnostic de detection associee |
Country Status (12)
Country | Link |
---|---|
US (1) | US7514211B2 (fr) |
EP (1) | EP1384777B1 (fr) |
JP (1) | JPWO2002079466A1 (fr) |
KR (1) | KR100890448B1 (fr) |
AT (1) | ATE432345T1 (fr) |
AU (1) | AU2002244949B2 (fr) |
CA (1) | CA2443146C (fr) |
DE (1) | DE60232442D1 (fr) |
DK (1) | DK1384777T3 (fr) |
ES (1) | ES2325807T3 (fr) |
PT (1) | PT1384777E (fr) |
WO (1) | WO2002079466A1 (fr) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1008648A1 (fr) * | 1997-05-15 | 2000-06-14 | Shunichi Shiozawa | Gene responsable de l'arthrite rhumatoide, methode pour diagnostiquer l'arthrite rhumatoide et procede permettant de determiner des facteurs responsables de l'arthrite rhumatoide |
EP1164190A1 (fr) * | 1999-03-20 | 2001-12-19 | Shunichi Shiozawa | Gene de la polyarthrite rhumatoide et procede permettant de diagnostiquer la polyarthrite rhumatoide |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6582908B2 (en) * | 1990-12-06 | 2003-06-24 | Affymetrix, Inc. | Oligonucleotides |
EP1100963A2 (fr) * | 1998-07-25 | 2001-05-23 | AstraZeneca AB | Polymorphismes du gene ccr-2 de l'homme |
EP1112381A1 (fr) * | 1998-09-19 | 2001-07-04 | AstraZeneca AB | Polymorphismes du gene humain de la sous-unite alpha 4 de l'integrine, appropries au diagnostic et au traitement des maladies mediees par un ligand d'integrine |
-
2002
- 2002-03-29 JP JP2002578468A patent/JPWO2002079466A1/ja active Pending
- 2002-03-29 AT AT02713262T patent/ATE432345T1/de active
- 2002-03-29 DE DE60232442T patent/DE60232442D1/de not_active Expired - Lifetime
- 2002-03-29 CA CA2443146A patent/CA2443146C/fr not_active Expired - Lifetime
- 2002-03-29 ES ES02713262T patent/ES2325807T3/es not_active Expired - Lifetime
- 2002-03-29 DK DK02713262T patent/DK1384777T3/da active
- 2002-03-29 AU AU2002244949A patent/AU2002244949B2/en not_active Expired
- 2002-03-29 KR KR1020037012783A patent/KR100890448B1/ko active IP Right Grant
- 2002-03-29 WO PCT/JP2002/003191 patent/WO2002079466A1/fr active Application Filing
- 2002-03-29 EP EP02713262A patent/EP1384777B1/fr not_active Expired - Lifetime
- 2002-03-29 US US10/473,368 patent/US7514211B2/en not_active Expired - Lifetime
- 2002-03-29 PT PT02713262T patent/PT1384777E/pt unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1008648A1 (fr) * | 1997-05-15 | 2000-06-14 | Shunichi Shiozawa | Gene responsable de l'arthrite rhumatoide, methode pour diagnostiquer l'arthrite rhumatoide et procede permettant de determiner des facteurs responsables de l'arthrite rhumatoide |
EP1164190A1 (fr) * | 1999-03-20 | 2001-12-19 | Shunichi Shiozawa | Gene de la polyarthrite rhumatoide et procede permettant de diagnostiquer la polyarthrite rhumatoide |
Non-Patent Citations (1)
Title |
---|
See also references of WO02079466A1 * |
Also Published As
Publication number | Publication date |
---|---|
US20040175706A1 (en) | 2004-09-09 |
CA2443146C (fr) | 2011-03-29 |
WO2002079466A1 (fr) | 2002-10-10 |
DE60232442D1 (de) | 2009-07-09 |
CA2443146A1 (fr) | 2002-10-10 |
KR100890448B1 (ko) | 2009-03-26 |
PT1384777E (pt) | 2009-06-12 |
EP1384777B1 (fr) | 2009-05-27 |
EP1384777A4 (fr) | 2005-06-01 |
ATE432345T1 (de) | 2009-06-15 |
JPWO2002079466A1 (ja) | 2004-07-22 |
DK1384777T3 (da) | 2009-09-07 |
ES2325807T3 (es) | 2009-09-18 |
KR20030093291A (ko) | 2003-12-06 |
AU2002244949B2 (en) | 2007-08-30 |
US7514211B2 (en) | 2009-04-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20080305967A1 (en) | Genetic Markers Associated with Endometriosis and Use Thereof | |
US11287425B2 (en) | Genetic markers associated with endometriosis and use thereof | |
EP1007738A1 (fr) | Procedes d'analyse des polymorphismes de synthese du ltc4 et utilisation diagnostique | |
US20200087728A1 (en) | Genetic markers associated with endometriosis and use thereof | |
JP2010519895A (ja) | クローン病座位における遺伝子型を決定する方法 | |
US8137916B2 (en) | Susceptibility gene for alzheimer's disease | |
EP2393939B1 (fr) | Marqueur snp de risque du cancer du sein et des ovaires | |
JP4242590B2 (ja) | 慢性関節リウマチの疾患感受性遺伝子、及びその利用 | |
EP1384777B1 (fr) | Adn genomiques participant a la polyarthrite rhumatoide, son procede de diagnostic, son procede d'estimation du risque d'apparition et trousse de diagnostic de detection associee | |
EP2764116B1 (fr) | Polymorphismes génétiques associés à une thrombose veineuse chez des femmes, leurs procédés de détection et leurs utilisations | |
JP6342627B2 (ja) | 筋萎縮性側索硬化症の新規病因遺伝子 | |
CN113166810A (zh) | 包括gba基因单碱基多态性的脑动脉瘤诊断用snp标志物 | |
KR101141546B1 (ko) | Ankrd15, hpd, psmd9, wdr66, gpc6, pax9, lrrc28, tns4, axl, 및 hnrpul1 유전자로부터 유래된 단일염기다형을 포함하는 폴리뉴클레오티드, 이를 포함하는 마이크로어레이 및 진단키트, 및 이를 이용한 분석방법 | |
EP1388590B1 (fr) | Test génétique de prédiction des risques de glaucome | |
WO2000006768A1 (fr) | Polymorphismes genetiques du gene du recepteur neurokininique 1 de l'homme et leurs utilisations pour le diagnostic et le traitement d'affections | |
JP4317376B2 (ja) | 糖尿病性腎症遺伝子の検出方法 | |
CN112424381A (zh) | 包括arhgap32基因单碱基多态性的脑动脉瘤诊断用snp标志物 | |
JP2002531144A (ja) | 第x因子および/または第xa因子仲介疾患の診断および処置における第x因子多型性の使用 | |
US20140309139A1 (en) | Genetic polymorphisms associated with venous thrombosis in women, methods of detection and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20031029 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20050415 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: BOHEST AG Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20090602 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REF | Corresponds to: |
Ref document number: 60232442 Country of ref document: DE Date of ref document: 20090709 Kind code of ref document: P |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2325807 Country of ref document: ES Kind code of ref document: T3 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090527 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20100302 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090828 Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100331 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100329 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090527 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100329 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090527 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PCAR Free format text: NEW ADDRESS: HOLBEINSTRASSE 36-38, 4051 BASEL (CH) |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 15 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 16 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 17 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20210210 Year of fee payment: 20 Ref country code: CH Payment date: 20210317 Year of fee payment: 20 Ref country code: NL Payment date: 20210212 Year of fee payment: 20 Ref country code: PT Payment date: 20210326 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20210316 Year of fee payment: 20 Ref country code: BE Payment date: 20210217 Year of fee payment: 20 Ref country code: AT Payment date: 20210225 Year of fee payment: 20 Ref country code: SE Payment date: 20210311 Year of fee payment: 20 Ref country code: GB Payment date: 20210318 Year of fee payment: 20 Ref country code: DK Payment date: 20210310 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20210407 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20210211 Year of fee payment: 20 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R071 Ref document number: 60232442 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MK Effective date: 20220328 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: EUP Expiry date: 20220329 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MK Effective date: 20220329 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: PE20 Expiry date: 20220328 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20220328 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: EUG |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK07 Ref document number: 432345 Country of ref document: AT Kind code of ref document: T Effective date: 20220329 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20220704 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20220406 Ref country code: ES Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20220330 |